Figure 1.

AAV6.2FF-2G4/AAV6.2FF-5D2 dose-reduction experiment

BALB/c mice (n = 8/group) were administered a range of total vector genomes (vg) of AAV6.2FF-2G4 and AAV6.2FF-5D2 intramuscularly, with each vector administered to separate muscle groups. Mock animals were administered a dose of 4 × 10¹¹ vg of AAV6.2FF expressing luciferase. 28 days following AAV administration, mice were challenged with 1000xLD₅₀ MA-EBOV and monitored for (A) survival and (B) weight loss (plotted as group averages). Survival of treated groups was compared with the mock group using the Mantel-Cox log rank test. ∗∗∗∗p < 0.0001.